Latest1 information on COVID-19
©2022 Stanford Medicine
Open Label Two-Arm Study to Evaluate Rilzabrutinib in IgG4-Related Disease Patients
Recruiting
I'm InterestedTrial ID: NCT04520451
Purpose
This is a Phase 2a, multi-center, open-label, two-arm study of approximately 25 patients with
active IgG4-related disease (IgG4-RD). The two arms include (1) Experimental: rilzabrutinib
with glucocorticoids and (2) Active Comparator: glucocorticoids only.
Official Title
An Open Label, Two-Arm Study to Evaluate the Effect of Rilzabrutinib (PRN1008/SAR444671) on Safety and Disease Activity in Patients With IgG4-Related Disease
Stanford Investigator(s)
Matthew C. Baker, MD MS
Assistant Professor of Medicine (Immunology and Rheumatology)
Reena Thomas, MD PhD
Clinical Associate Professor, Neurology & Neurological Sciences Clinical Associate Professor (By courtesy), Neurosurgery
Eligibility
Key Inclusion Criteria:
- Be male or female with age ≥18 years.
- Have a clinical diagnosis of IgG4-RD.
- Be willing to taper off an equivalent prednisone dose of between 20-40 mg/day in 2
weeks.
Key Exclusion Criteria:
- Currently or within 6 months of screening taking rituximab, other B-cell depleting
agents, or alkylating agents unless B cell concentrations have been demonstrated by
flow cytometry to return to normal values (defined as 5 cells per cubic mm).
- History of solid organ transplant
- Positive at Screening for HIV, hepatitis B, hepatitis C, or TB
- Female patients who are pregnant or nursing.
- NOTE: Other Inclusion/Exclusion criteria may apply.
Intervention(s):
drug: rilzabrutinib
drug: Glucocorticoids
Recruiting
I'm InterestedContact Information
Stanford University
School of Medicine
300 Pasteur Drive
Stanford,
CA
94305
Angie Aberia
650-723-8516